Daily Roundup

Accent Group Ltd is navigating a challenging retail environment as it reported a 1.9% decline in sales for the first 19 weeks of FY27, with like-for-like sales falling 3.9%. The downturn reflects broader headwinds including elevated fuel prices, rising interest rates, and weakening consumer confidence. While the company has managed to improve its gross margin and is rolling out initiatives from its 2030 Strategic Growth Plan, these gains have been offset by softer demand. The retailer is now pinning hopes on the critical trading period ahead, which encompasses Black Friday, Cyber Monday, Christmas, and back-to-school shopping.

Smart Parking Ltd is telling a starkly different story. The company delivered a strong FY26 performance with record revenue of $126.0 million and adjusted EBITDA jumping 37% to $30.8 million. A significant win came in the form of positive regulatory developments in the UK, where a new Private Parking Code of Practice has been established. Looking ahead, management is confident about hitting FY27 targets, with expectations for a $5 million EBITDA benefit in the UK and Germany expected to reach break-even during the year. The company has also signaled its growth ambitions by relocating its CEO to the US to spearhead long-term expansion efforts.

In the medical technology space, Artrya Limited has secured a meaningful foothold in the U.S. market. The company announced a five-year commercial agreement with HonorHealth, a major Arizona health system serving approximately five million people. This deal, valued at a minimum of US$0.5 million over five years, marks Artrya's fifth U.S. customer and notably, its first inbound customer acquired outside its foundation customer base and SAPPHIRE study participants. The win demonstrates growing market recognition for Artrya's Salix® AI-powered cloud platform and opens new customer acquisition channels in the crucial American market.

Imricor Medical Systems is firing on multiple cylinders as it scales its U.S. operations. The company kicked off its commercial launch with Rady Children's Hospital-San Diego as its first customer, establishing the country's first commercial interventional MR cardiac catheterization program. Children's Medical Center Dallas quickly followed as the second customer. On the regulatory front, Imricor secured FDA clearances for pediatric label expansions and made progress on its Vision-MR Ablation Catheter application. Strategic partnerships with Philips are also opening doors, with a joint iMR lab solution now live. Financially, the company reported Q3 revenue of US$188,000, a remarkable 437% jump from the prior year period, though it posted a net loss of $2.9 million for the quarter as it invests heavily in growth.

Finally, Centrepoint Alliance Ltd capped off five years of disciplined execution with another strong FY26 showing. Normalised EBITDA climbed 16% to $12.3 million with margins expanding to 29%, while net revenue surged 53% to $43.0 million. The company's cost-to-income ratio has compressed impressively from 88% to 71% over the five-year period. As Australia's largest adviser network with 576 advisers under its licence, Centrepoint is seeing its salaried advice business emerge as a material growth driver, with revenue rising 22% to $10.3 million. The company rewarded shareholders with a fully franked final dividend of 1.75 cents per share, bringing total FY26 dividends to 3.0 cents. Since February 2021, Centrepoint has delivered a cumulative total shareholder return of 130%.